Nautilus Q1 net loss narrows 12% to $14.7 million; R&D expense falls 16% to $9.7 million
PUBT · 04/28 20:31
Share
Listen to the news
- Nautilus Biotechnology posted a net loss of USD 14.7 million for Q1 2026, narrowing 12%.
- Revenue remained at no revenue.
- Total operating expenses fell 14% to USD 16.12 million.
- Cash, cash equivalents and short-term investments totaled USD 95.9 million as of March 31, 2026.
- Iterative Mapping Early Access Program launched in January 2026 with Tau service offerings, with pre-orders expected to open in late 2026 and first instrument installations targeted for early 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nautilus Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001808805-26-000022), on April 28, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved